AIM: To assess sustained virological response (SVR) rates in a predominantly hepatitis C virus (HCV) genotype 4 infected population. METHODS: Between 2003-2007, 240 patients who were treated for chronic hepatitis C infection at our center were included. Epidemiological data, viral genotypes, and treatment outcomes were evaluated in all treated patients. Patients with chronic renal failure, previous non-responders, and those who relapsed after previous treatment were excluded from the study. Among all patients, 57% were treated with PEG-interferon (IFN) alpha-2a and 43% patients were treated with PEG-IFN alpha-2b; both groups received a standard dose of ribavirin. RESULTS: 89.6% of patients completed the treatment with an overall SVR rate of 58%. The SVR rate was 54% in genotype 1, 44% in genotype 2, 73% in genotype 3, and 59% in genotype 4 patients. There was no statistical difference in the SVR rate between patients treated with PEG-IFN alpha-2a and PEG-IFN alpha-2b (61.5% vs 53%). Patients younger than 40 years had higher SVR rates than older patients (75% vs 51%, P = 0.001). SVR was also statistically significantly higher when the HCV RNA load (pretreatment) was below 800.000 (64% vs 50%, P = 0.023), in patients with a body mass index (BMI) less than 28 (65% vs 49%, P = 0.01), and in patients who completed the treatment duration (64% vs 8%, P <or= 0.00001). CONCLUSION: The SVR rate in our study is higher than in previous studies. Compliance with the standard duration of treatment, higher ribavirin dose, younger age, lower BMI, and low pretreatment RNA levels were associated with a higher virological response.
AIM: To assess sustained virological response (SVR) rates in a predominantly hepatitis C virus (HCV) genotype 4 infected population. METHODS: Between 2003-2007, 240 patients who were treated for chronic hepatitis C infection at our center were included. Epidemiological data, viral genotypes, and treatment outcomes were evaluated in all treated patients. Patients with chronic renal failure, previous non-responders, and those who relapsed after previous treatment were excluded from the study. Among all patients, 57% were treated with PEG-interferon (IFN) alpha-2a and 43% patients were treated with PEG-IFN alpha-2b; both groups received a standard dose of ribavirin. RESULTS: 89.6% of patients completed the treatment with an overall SVR rate of 58%. The SVR rate was 54% in genotype 1, 44% in genotype 2, 73% in genotype 3, and 59% in genotype 4 patients. There was no statistical difference in the SVR rate between patients treated with PEG-IFN alpha-2a and PEG-IFN alpha-2b (61.5% vs 53%). Patients younger than 40 years had higher SVR rates than older patients (75% vs 51%, P = 0.001). SVR was also statistically significantly higher when the HCV RNA load (pretreatment) was below 800.000 (64% vs 50%, P = 0.023), in patients with a body mass index (BMI) less than 28 (65% vs 49%, P = 0.01), and in patients who completed the treatment duration (64% vs 8%, P <or= 0.00001). CONCLUSION: The SVR rate in our study is higher than in previous studies. Compliance with the standard duration of treatment, higher ribavirin dose, younger age, lower BMI, and low pretreatment RNA levels were associated with a higher virological response.
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: C Payan; F Roudot-Thoraval; P Marcellin; N Bled; G Duverlie; I Fouchard-Hubert; P Trimoulet; P Couzigou; D Cointe; C Chaput; C Henquell; A Abergel; J M Pawlotsky; C Hezode; M Coudé; A Blanchi; S Alain; V Loustaud-Ratti; P Chevallier; C Trepo; V Gerolami; I Portal; P Halfon; M Bourlière; M Bogard; E Plouvier; C Laffont; G Agius; C Silvain; V Brodard; G Thiefin; C Buffet-Janvresse; G Riachi; F Grattard; T Bourlet; F Stoll-Keller; M Doffoel; J Izopet; K Barange; M Martinot-Peignoux; M Branger; A Rosenberg; P Sogni; M L Chaix; S Pol; V Thibault; P Opolon; A Charrois; L Serfaty; B Fouqueray; J D Grange; J J Lefrère; F Lunel-Fabiani Journal: J Viral Hepat Date: 2005-07 Impact factor: 3.728
Authors: Hamad Al Ashgar; Mohammed Q Khan; Ahmed Helmy; Khalid Al Swat; Abdullah Al Shehri; Abdalla Al Kalbani; Musthafa Peedikayel; Khalid Al Kahtani; Mohammed Al Quaiz; Mohammed Rezeig; Ingvar Kagevi; Mohammed Al Fadda Journal: Saudi J Gastroenterol Date: 2008-04 Impact factor: 2.485
Authors: Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill Journal: Ann Intern Med Date: 2004-03-02 Impact factor: 25.391
Authors: J M Barrera; M Bruguera; M G Ercilla; C Gil; R Celis; M P Gil; M del Valle Onorato; J Rodés; A Ordinas Journal: Hepatology Date: 1995-03 Impact factor: 17.425
Authors: Sami A Gabr; Ahmad H Alghadir; Ahmed A Allam; Jamaan Ajarem; Ghada Al-Basher; Mostafa A Abdel-Maksoud; Ayman A Ghfar; Alaa Aboud Journal: Clin Interv Aging Date: 2016-05-04 Impact factor: 4.458